ELEVATED SERUM LEVELS OF IL-17 DURING DISEASE ACTIVITY OF ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW WITH META-ANALYSIS

• DOI: 10.22533/at.ed.1592116111

• Palavras-chave: Case control studies; expression IL-17; IL-23 and IL-17 pathway.

• Keywords: case control studies; expression IL-17; IL-23 and IL-17 pathway

• Abstract:

  Concentrations of serum IL-17 have been found at high levels in patients with AS. The role of serum IL-17 in ankylosing spondylitis (AS) was investigated through a meta-analysis undertaken to examine the correlation between AS disease activity and serum levels of IL-17 in AS compared to healthy controls and AS patients. Searches were performed in PubMed, ScienceDirect, Cochrane, and Lilacs databases for pertinent case-control studies using with the descriptors “Spondylitis, Ankylosing” and “Interleukin-17”. Expression in relation to healthy controls and correlation of IL-17 with BASDAI were plotted using Review Manager 5.3 software. Quality assessment of each eligible study used the Newcastle-Ottawa Scale. Thirteen case-control studies were selected for this meta-analysis and contained a pooled total of 752 AS patients and 607 healthy controls. Our main result revealed strikingly higher levels of serum IL-17 in AS patients, compared to healthy controls. Pooled mean difference 14.59, pooled risk ratios (RRs) with 95% confidence intervals (CIs) 7.73, 21.45; p<0.00001. Serum IL-17 is highly expressed in serum of patients with AS and is related to disease activity. The treatment in use significantly influenced IL-17; however, we did not observe a significant difference in the expression of IL-17 in the treatment of patients taking anti-TNF, proving that it does not interfere in this pathway.

• Número de páginas: 14